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Background: Chronic inflammation has been implicated in the pathogenesis of several cancers,
including lung and laryngeal cancer. The objective of the study is to elucidate the association
between ICS use and diagnosis of lung and laryngeal cancer.
Methods: A nested caseecontrol study based on the Korean national claims database included
new adult users of inhaled medications between January 1, 2007, and December 31, 2010.
Patients diagnosed with lung cancer or laryngeal cancer after enrollment were identified as
cases and up to five control individuals matched for age, sex, diagnosis of asthma or COPD,
Charlson Comorbidity Index scores, number of health care visits, and initiation date were
selected.
Results: From the 792,687 eligible cohort, 9177 individuals diagnosed with lung cancer were
matched with 37,048 controls. Additionally, 408 laryngeal cancer patients and 1651 controls
were matched. ICS use was associated with a decreased rate of lung cancer diagnosis [adjusted
odds ratio (aOR), 0.79; 95% confidence interval (CI), 0.69e0.90]. The inverse association
between ICS use and lung cancer risk was dose dependent (P < 0.0001 for the trend). However,
no reduction in the risk of laryngeal cancer among ICS users was identified (aOR, 1.06; 95% CI,
0.62e1.18).
Conclusion: The use of ICS is associated with a reduced risk of lung cancer but not of laryngeal
cancer.
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Inhaled corticosteroids and lung/laryngeal cancers 1223Introduction flunisolide), short-acting inhaled b2-agonists (SABA; salbu-Inhaled corticosteroids (ICS) uses a cornerstone treatment
for chronic airway diseases, including asthma1 and chronic
obstructive pulmonary disease (COPD).2 For patients with
asthma,3 ICS reduces asthma symptoms,3 improves lung
function and quality of life,3 reduces the frequency and
severity of exacerbations,4 and decreases asthma
mortality.5 Among patients with COPD, ICS improves quality
of life,6 and reduces symtoms.6,7
The benefit of ICS in patients with asthma8 or COPD9,10 is
based mainly on its anti-inflammatory effects. Given that
chronic inflammation has been implicated in the patho-
genesis of several cancers, including lung cancer and head
and neck cancers,11,12 the chemopreventive efficacy of
inhaled budesonide was tested for its effect on lung
carcinogenesis in mice and was reported to be effective.13
Additionally, a report proposing that ICS may prevent
development of lung cancer was published recently,14
although the association between ICS and laryngeal
cancer was not investigated.
Patients with COPD and asthma use ICS frequently and
are a high risk group for lung and laryngeal cancers.15e17 In
this context, we examined the association between ICS use
and diagnoses of lung and laryngeal cancers by analyzing
the Health Insurance Review and Assessment Service
database, which includes records for almost all South
Koreans.Material and methods
Source of data
We used the database of the Health Insurance Review and
Assessment Service (HIRA, Seoul, South Korea), a govern-
ment-affiliated agency responsible for examining the
accuracy of claims quality for National Health Insurance
(NHI, which covers approximately 96.6% of the entire 48.6
million South Korean population) and National Medical Aid
(covering approximately 3.5% of the South Korean pop-
ulation). The NHI database includes the entire South Korean
population as well as registered foreign-nationality resi-
dents as a compulsory insurance system, with exceptions
for cases applicable to the National Medical Aid program or
foreign military personnel.18 The HIRA database contains
information on demographics and all medical services
rendered, along with the diagnostic code (ICD-10 code) and
all prescription medications dispensed. Values in key fields
such as drug name, quantity, date dispensed, and duration
are missing or out of range in <0.5% of records. These
databases have been used in previous studies.19e23
Study design
A nested caseecontrol study was conducted based on the
HIRA database. The source population consisted of all
individuals who were dispensed at least one of the
following inhaled respiratory medications between January
1, 2007, and December 31, 2010: ICS, (beclomethasone,
budesonide, triamcinolone, ciclesonide, fluticasone, ortamol, fenoterol, procaterol, or terbutaline), long-acting
inhaled b2-agonists (LABA; salmeterol or formoterol),
short-acting inhaled muscarinic antagonists (SAMA; ipra-
tropium), long-acting inhaled muscarinic antagonists
(LAMA; tiotropium), a combination of SABA and SAMA
(ipratropium/salbutamol), or a combination of LABA and
ICS (budesonide/formoterol, fluticasone/salmeterol).
The eligible cohort of new users of inhaled respiratory
medication was identified from all individuals who had
a prescription for an inhaled respiratory medication for 30
days or longer between January 1, 2007, and December 31,
2010. The date of the first use of the above inhaled respi-
ratory medications was called the initiation date. Individ-
uals who had had a prescription for inhaled respiratory
medication for 30 days or longer or who had any of the ICD-
10 cancer diagnoses (C00eC97, D00eD09) within the year
prior to the initiation date were excluded. Additionally,
individuals <20 years of age or >120 years were also
excluded. The eligible individuals were monitored until the
diagnosis of lung cancer or head and neck cancer or until
December 31, 2010.
The protocol of this study was approved by the ethics
review committee of the National Evidence-based Health-
care Collaborating Agency, Seoul, Republic of Korea.
Case definition
Within the eligible cohort, we identified case individuals
based on ICD-10 diagnoses of lung cancer (C33eC34, D02.1,
D02.2) or head and neck cancer other than thyroid cancer
(C00eC14, C30eC32, D00.0, D02.0, D02.3) that occurred
after the initiation date of the inhaled respiratory medi-
cations. The index date was defined as the date of first
assignment of the above ICD-10 codes.
Control individuals
For each case individual, up to five control individuals, who
were randomly matched for age (within 1 year), sex,
diagnosis of asthma (J45eJ46) or COPD (J41eJ44), number
of health care utilizations (number of hospitalizations [1]
and number of outpatient visits [3]), and initiation date
(within 15 days), were selected without replication from
among individuals without an ICD-10 diagnosis of lung or
head and neck cancer. The index date for the controls was
defined as the index date for their matched case.
Inhaled corticosteroid exposure
ICS included orally inhaled beclomethasone, budesonide,
triamcinolone, ciclesonide, fluticasone, or flunisolide,
whether dispensed alone or in a combination inhaler with an
inhaled b2-agonist. The estimation of equivalencies was
chosen based on relative topical potency and what experts
consider to be comparable doses according to the National
Asthma Education and Prevention Program Expert Panel
report 3,24 the Canadian AsthmaConsensus Statement,25 and
the Global Strategy for Asthma Management and Prevention
2010 (updated).26 Accordingly, the equivalent doses for ICS
were 100 mg beclomethasone, 50 mg beclomethasone HFA,
Figure 1 Selection of the study population.
1224 C.-H. Lee et al.80 mg budesonide, 200 mg triamcinolone, 32 mg ciclesonide,
50 mg fluticasone, and 200 mg flunisolide. All doses were
converted to fluticasone equivalents and average daily doses
were categorized as high (fluticasone, 1000 mg/d or more),
moderate (fluticasone, 500e999 mg/d), and low (fluticasone,
<500 mg/d) according to defined daily doses of the most
recent prescription in the 60 days before the index date.27,28
Total number of prescribed ICS was counted and an ICS
user was defined as current if ICS prescriptions for 30 days
or longer were identified for the period within 90 days
before the index date. If ICS prescriptions for 30 days or
longer were identified for the period between 91 and 365
days before the index date, the patients were classified as
past users. If the ICS prescriptions were for shorter than 30
days, patients were regarded as non-users.Covariates
We adjusted for inhaled respiratory medication other than
ICS, overall comorbidity, and cumulative dose of oralcorticosteroids (OCS) used. Inhaled respiratory medication
other than ICS encompassed SABA, LABA, SAMA, SABA/SAMA,
and LAMA which were used within 1 year prior to the index
date. Overall comorbidity was adjusted using the Charson
Comorbidity Index, a validated risk-adjustment scoring
system used in outcomes researches.29,30 The cumulative
doses of OCS used during 1 year before the index date were
calculatedandused for adjusting the cancer risk according to
ICS use. The OCS prescriptions were converted to prednisone
using the following equivalent doses: 1 mg hydrocortisone
(cortisol), 1.6 mg cortisone, 4 mg prednisone, 5 mg prednis-
olone, 4 mg methylprednisolone, 4 mg triamcinolone,
0.03 mg betamethasone, and 0.03 mg dexamethasone.31
Smoking status was not included as a covariate because the
HIRA database does not include smoking status.Statistical analysis
Baseline characteristics including, age, sex, comorbidities,
number of health care utilizations, and inhaled respiratory
Table 1 Baseline characteristics of the cases and controls.
Characteristics Lung cancer
(N Z 9177)
Control
(N Z 37,048)
Laryngeal cancer
(N Z 408)
Control
(N Z 1651)
Sex
Male 6295 (68.60) 25,224 (68.08) 339 (83.09) 1375 (83.28)
Female 2882 (31.40) 11,824 (31.92) 69 (16.91) 276 (16.72)
Age (years)a
Mean (SD) 68.66 (10.32) 68.07 (10.32) 67.21 (10.15) 66.84 (10.16)
Median (Q1, Q3) 70 (63, 76) 70 (63, 75) 68 (62,74) 68 (62,73)
20e29 31 (0.34) 129 (0.35) 3 (0.74) 10 (0.61)
30e39 100 (1.09) 486 (1.31) 4 (0.98) 20 (1.21)
40e49 349 (3.80) 1499 (4.05) 13 (3.19) 61 (3.69)
50e59 1058 (11.53) 4503 (12.15) 56 (13.73) 221 (13.39)
60e69 2847 (31.02) 11,901 (32.12) 143 (35.05) 599 (36.28)
70e79 3688 (40.19) 14,665 (39.58) 153 (37.50) 621 (37.61)
80 1104 (12.03) 3865 (10.43) 36 (8.82) 119 (7.21)
Respiratory diseasesb
COPD (J41eJ44) 5311 (57.87) 21,051 (56.82) 242 (59.31) 950 (57.54)
Asthma (J45eJ46) 2558 (27.87) 11,512 (31.07) 113 (27.70) 482 (29.19)
Bronchiectasis (J47) 700 (7.63) 2217 (5.98) 21 (5.15) 86 (5.21)
TB sequel (B90) 257 (2.80) 871 (2.35) 9 (2.21) 36 (2.18)
Othersc 7 (0.08) 36 (0.10) 3 (0.18)
Not documented 344 (3.75) 1361 (3.67) 23 (5.64) 94 (5.69)
Charlson comorbidity
indexb
0e1 3201 (34.88) 14,548 (39.27) 142 (34.80) 669 (40.52)
2e3 3535 (38.52) 14,820 (40.00) 157 (38.48) 665 (40.28)
4 2441 (26.60) 7680 (20.73) 109 (26.72) 317 (19.20)
Health care utilizationb
Number of
hospitalization
Mean (SD) 0.79 (1.28) 0.5 (0.94) 0.8 (1.23) 0.48 (0.88)
Median (Q1, Q3) 0 (0, 1) 0 (0, 1) 0 (0,1) 0 (0,1)
0 5061 (55.15) 24,721 (66.73) 213 (52.21) 1099 (66.57)
1 2501 (27.25) 8802 (23.76) 125 (30.64) 411 (24.89)
2 1615 (17.60) 3525 (9.51) 70 (17.16) 141 (8.54)
Number of outpatient
visit
Mean (SD) 29.89 (40.50) 22.82 (32.18) 29.81 (44.31) 21 (33.73)
Median (Q1, Q3) 14 (5, 39) 10 (3, 30) 13 (5,37) 8 (3,26)
<15 4643 (50.59) 21,652 (58.44) 220 (53.92) 1052 (63.72)
15e30 1657 (18.06) 6383 (17.23) 68 (16.67) 235 (14.23)
31e50 1109 (12.08) 3982 (10.75) 38 (9.31) 164 (9.93)
>50 1768 (19.27) 5031 (13.58) 82 (20.10) 200 (12.11)
Number of ER visit
Mean (SD) 0.45 (1.52) 0.33 (0.87) 0.36 (0.89) 0.32 (0.73)
Median (Q1, Q3) 0 (0, 0) 0 (0, 1) 0 (0,0) 0 (0,0)
0 6737 (73.41) 28,996 (78.27) 311 (76.23) 1288 (78.01)
1 2440 (26.59) 8052 (21.73) 97 (23.77) 363 (21.99)
SD: standard deviation; Q1: first quartile; Q3: third quartile; COPD: chronic obstructive pulmonary disease; TB: tuberculosis; ER:
emergency room.
a Age at initiation date.
b Within 1-year prior to index date.
c Includes interstitial lung diseases (J84), rheumatoid lung diseases (J99), and sarcoidosis (D86).
Inhaled corticosteroids and lung/laryngeal cancers 1225medication use of cases and control patients were
summarized by descriptive statistics such as proportion,
mean, standard deviation, median, and interquartile range.
The association between the use of inhaled respiratory
medication and lung or head and neck cancer wereinvestigated by conditional logistic regression. Continuous
variables were categorized into appropriate categorical
variables based on the distributions. Likelihood ratio tests
were used to examine the goodness of fit of the model, and
no significant lack of fit was found. Adjusted odd ratios
Table 2 Risk of lung cancer according to use of inhalers.
Lung cancer
(N Z 9177)
Control
(N Z 37,048)
Crude OR
(95% CI)
p-value Adjusted
OR (95% CI)
p-valuec Adjusted
OR (95% CI)
p-valued
ICS
Non-ICS usersa 6531 (71.17) 25,677 (69.31) 1(ref) 1(ref) 1(ref)
ICS usersb 2646 (28.83) 11,371 (30.69) 0.88
(0.83e0.93)
<0.001 0.79
(0.69e0.9)
<0.001 0.88
(0.83e0.93)
<0.001
LABA
Non-LABA usersa 6709 (73.11) 26,636 (71.90) 1(ref) 1(ref)
LABA userb 2468 (26.89) 10,412 (28.10) 0.91
(0.86e0.96)
<0.001 1.12
(0.98e1.29)
0.090
LAMA
Non-LAMA usersa 7995 (87.12) 32,862 (88.70) 1(ref) 1(ref) 1(ref)
LAMA userb 1182 (12.88) 4186 (11.30) 1.10
(1.02e1.19)
0.02 1.10
(1.02e1.19)
0.016 1.10
(1.02e1.19)
0.01
Cumulative dose
of ICS (mg)
Mean (SD) 24,796.81
(35,080.32)
22,504.3
(31,139.47)
Median (Q1, Q3) 15,000
(4,000, 30,000)
15,000
(5500, 30,000)
P value for
trende
<0.001 <0.001 <0.001
0 dose 4748 (51.74) 18,313 (49.43) 1(ref) 1(ref) 1(ref)
<5000 1181 (12.87) 4289 (11.58) 1.19
(1.1e1.28)
<0.001 1.18
(1.09e1.28)
<0.001 1.18
(1.09e1.28)
<0.001
5000e14,999 826 (9.00) 4265 (11.51) 0.86
(0.79e0.94)
<0.001 0.86
(0.78e0.94)
<0.001 0.86
(0.79e0.94)
<0.001
15,000 723 (7.88) 3635 (9.81) 0.80
(0.73e0.88)
<0.001 0.81
(0.71e0.92)
<0.001 0.80
(0.73e0.88)
<0.001
15,001e29,999 433 (4.72) 1769 (4.77) 0.99
(0.88e1.11)
0.81 0.98
(0.85e1.13)
0.77 0.97
(0.87e1.09)
0.64
30,000 314 (3.42) 1381 (3.73) 0.88
(0.77e1)
0.05 0.88
(0.74e1.03)
0.11 0.87
(0.76e0.99)
0.04
>30,000 952 (10.37) 3396 (9.17) 1.02
(0.94e1.11)
0.69 1.01
(0.88e1.15)
0.92 1.00
(0.92e1.09)
0.99
OR: odds ratio; CI: confidence interval; ICS: inhaled corticosteroid; LABA: long-acting inhaledb2-agonists; LAMA: long-acting inhaled
muscarinic antagonists; SD: standard deviation; Q1: first quartile; Q3: third quartile.
a Defined if inhaler prescriptions shorter than 30 days during 1 year before the index date was identified.
b Defined if inhaler prescriptions 30 days or longer during 1 year before the index date was identified.
c Adjusted for LABA use, LAMA use, SABA use, SAMA use, OCS use.
d Adjusted for LAMA use, SABA use, SAMA use, OCS use.
e Linear logit model: used each group median.
1226 C.-H. Lee et al.(aORs) are presented with 95% confidence intervals (CIs)
and a P-value. To explore the doseeresponse relationship,
we initially divided the distribution of the cumulative ICS
dose into <15,000 mg, 15,000 mg, 15,001e29,999 mg,
30,000 mg, and >30,000 mg because patients with cumula-
tive ICS dose of 15,000 mg or 30,000 mg were common. In
addition, we divided the group with ICS 15,000 mg into
5000 mg and 5000e14,999 mg because more than 20% of
patients were classified into the group with ICS dose
<15,000 mg. Tests for trends were performed using the
medians of each group as continuous variables in a linear
logit model.
A protopathic bias can occur when early symptoms of
undetected cancer could affect the use of ICS.32 We per-
formed a sensitivity analysis to explore the impact of proto-
pathic bias using 3-, 6-, and 12-month lag-time analysis. Therisk of cancer according to ICS was calculated after ignoring
the use of ICS within the lag time prior to the index date.
All data manipulation and statistical analyses were
performed using SAS 9.1.3 (SAS Institute, Cary, NC, USA). A
P-value <0.05 was considered statistically significant.Results
We identified 1,341,229 individuals with prescriptions for
inhaled respiratory medications with a duration of 30 days
or longer between January 1, 2007, and December 31,
2010. Among them, 203,230 individuals who had had
previous prescriptions for inhaled respiratory medications
for 30 days or longer during the year before the current
initiation of inhaled respiratory medication were excluded.
Table 3 Sensitivity analysis for risk of lung cancer according to use of inhalers.
Lung cancer (N Z 9177) Control (N Z 37,048) Crude OR (95% CI) p-value Adjusted OR (95% CI) p-valuec Adjusted OR (95% CI) p-valued
Use of inhalers till 3 months prior to index date
ICS
Non-ICS usersa 7600 (82.82) 30,576 (82.53) 1(ref) 1(ref) 1(ref)
ICS usersb 1577 (17.18) 6472 (17.47) 0.87 (0.8e0.93) <0.001 0.73 (0.6e0.87) <0.001 0.86 (0.8e0.93) <0.001
LABA
Non-LABA usersa 7694 (83.84) 31,089 (83.92) 1(ref) 1(ref)
LABA userb 1483 (16.16) 5959 (16.08) 0.90 (0.84e0.97) 0.01 1.21 (1e1.45) 0.05
LAMA
Non-LAMA usersa 8501 (92.63) 34,747 (93.79) 1(ref) 1(ref) 1(ref)
LAMA userb 676 (7.37) 2301 (6.21) 1.04 (0.94e1.15) 0.50 1.04 (0.94e1.15) 0.46 1.04 (0.94e1.16) 0.41
Cumulative dose of ICS(mg)
Mean (SD) 41,151.45 (64,662.91) 37,855.08 (57,556.10)
Median (Q1, Q3) 15,000 (12,500, 45,000) 15,000 (15,000, 42,000)
P value for trende <0.001 <0.001 <0.001
0 dose 5989 (65.26) 24,650 (66.54) 1(ref) 1(ref) 1(ref)
< 5000 539 (5.87) 1388 (3.75) 1.21 (1.07e1.35) <0.001 1.19 (1.06e1.34) <0.001 1.19 (1.06e1.34) <0.001
5000e14,999 278 (3.03) 1330 (3.59) 0.70 (0.61e0.81) <0.001 0.66 (0.57e0.77) <0.001 0.69 (0.6e0.8) <0.001
15,000 797 (8.68) 3485 (9.41) 0.77 (0.7e0.84) <0.001 0.72 (0.65e0.8) <0.001 0.75 (0.69e0.83) <0.001
15,001e29,999 229 (2.50) 1028 (2.77) 0.70 (0.6e0.82) <0.001 0.66 (0.56e0.77) <0.001 0.69 (0.59e0.81) <0.001
30,000 352 (3.84) 1567 (4.23) 0.75 (0.66e0.85) <0.001 0.69 (0.6e0.8) <0.001 0.74 (0.65e0.84) <0.001
>30,000 993 (10.82) 3600 (9.72) 0.84 (0.76e0.92) <0.001 0.76 (0.67e0.85) <0.001 0.83 (0.76e0.91) <0.001
Use of inhalers till 6 months prior to index date
ICS
Non-ICS usersa 8188 (89.22) 33,075 (89.28) 1(ref) 1(ref) 1(ref)
ICS usersb 989 (10.78) 3973 (10.72) 0.87 (0.8e0.95) <0.001 0.73 (0.57e0.92) <0.001 0.87 (0.8e0.95) <0.001
LABA
Non-LABA usersa 8242 (89.81) 33,369 (90.07) 1(ref) 1(ref)
LABA userb 935 (10.19) 3679 (9.93) 0.90 (0.82e0.98) 0.02 1.22 (0.96e1.55) 0.11
LAMA
Non-LAMA usersa 8750 (95.35) 35,633 (96.18) 1(ref) 1(ref) 1(ref)
LAMA userb 427 (4.65) 1415 (3.82) 1.01 (0.89e1.15) 0.84 1.02 (0.9e1.16) 0.73 1.03 (0.91e1.16) 0.69
Cumulative dose of ICS (mg)
Mean (SD) 40,805.41 (62,613.92) 37,723.03 (56,714.54)
Median (Q1, Q3) 15,000 (12,500, 45,000) 15,000 (15,000, 42,812.5)
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1228 C.-H. Lee et al.Additionally, 62,097 individuals with ICD-10 diagnoses of
cancers that had been present during the 1-year period
before the indexdate aswell as 283,215 individualswhowere
aged <20 years, aged >120 years, or unknown age were
excluded. Finally, a cohort of 792,687 new users of inhaled
respiratory medication was identified (Fig. 1).
During the study period, 14,830 individuals in this cohort
were newly diagnosed with lung cancer and 588 with
laryngeal cancer.
Patients with lung cancer and controls
For the 9177 individuals with lung cancer, we identified
37,048 controls matched for age, sex, a diagnosis of asthma
or COPD, Charlson Comorbidity Index scores, and the
number of hospital visits (Fig. 1). 68.6% of lung cancer
patients and 68.1% of controls were male. The mean ages of
the patients with lung cancer and of controls were 68.7 and
68.1 years, respectively. COPD and asthma were the most
common respiratory diseases among them. Regarding the
Charlson Comorbidity Index, 26.6% of patients with lung
cancer and 20.7% of controls had scores of 4 or higher. The
number of hospitalizations, outpatient visits, and ER visits
were similar between the groups (Table 1).
Impact of inhaled corticosteroids on lung cancer
risk
After adjusting for differences in the covariates, ICS use
was associated with a decreased rate of lung cancer diag-
nosis (aOR, 0.79; 95% CI, 0.69e0.90). Additionally, the
association between ICS use and a decreased risk of lung
cancer was dose dependent (P < 0.001for the trend; Table
2). This association was maintained in sensitivity analyses
using 3- and 6-month lag-time analyses (Table 3).
Although LABA use was not associated with the risk of
lung cancer, LAMA use was associated with an increased risk
of lung cancer (aOR, 1.10; 95% CI, 1.02e1.19). However,
the association between LAMA use and lung cancer dis-
appeared in the sensitivity analyses (Table 3).
Patients with laryngeal cancer and controls
For the 408 individuals with laryngeal cancer, we identified
1651 matched for age, sex, asthma or COPD, Charlson
Comorbidity Index score, and number of hospital visits.
In total, 83.1% of patients with laryngeal cancer and
83.3% of controls were male. The mean ages of the cases
and controls were 67.2 and 66.8 years, respectively.
Asthma and COPD were the most common diseases. In total,
26.7% of the cases and 19.2% of the controls had scores of 4
or higher on the Charlson Comorbidity Index. The number of
hospitalizations, outpatient visits, and ER visits were
similar between the groups (Table 1).
Impact of inhaled corticosteroids on laryngeal
cancer risk
ICS use (aOR, 1.06; 95% CI, 0.63e1.18), LABA use (aOR,
0.82; 95% CI, 0.48e1.40), and LAMA use (aOR, 0.77; 95% CI,
Table 4 Risk of laryngeal cancer according to use of inhalers.
Laryngeal cancer
(N Z 408)
Control
(N Z 1651)
Crude OR
(95% CI)
p-value Adjusted
OR(95% CI)
p-valuec Adjusted
OR (95% CI)
p-valued
ICS
Non-ICS usersa 277 (67.89) 1101 (66.69) 1(ref) 1(ref) 1(ref)
ICS usersb 131 (32.11) 550 (33.31) 0.88
(0.67e1.06)
0.37 1.06
(0.63e1.18)
0.82 0.90
(0.68e1.19)
0.45
LABA
Non-LABA usersa 294 (72.06) 1160 (70.26) 1(ref) 1(ref)
LABA userb 114 (27.94) 491 (29.74) 0.85
(0.64e1.12)
0.24 0.82
(0.48e1.40)
0.46
LAMA
Non-LAMA
usersa
358 (87.75) 1432 (86.74) 1(ref) 1(ref) 1(ref)
LAMA userb 50 (12.25) 219 (13.26) 0.75
(0.52e1.10)
0.14 0.77
(0.53e1.13)
0.19 0.77
(0.53e1.12)
0.17
Cumulative dose of ICS (mg)
Mean (SD) 21,935.98
(29,605.92)
22,523.79
(28,940.26)
Median
(Q1, Q3)
15,000
(4000, 27,000)
15,000
(6750, 30,000)
P value
for trende
0.11 0.10 0.11
0 dose 200 (49.02) 803 (48.64) 1(ref) 1(ref) 1(ref)
<5000 56 (13.73) 159 (9.63) 1.66
(1.14e2.43)
0.01 1.67
(1.14e2.45)
0.01 1.67
(1.14e2.45)
0.01
5000e
14,999
39 (9.56) 195 (11.81) 0.94
(0.63e1.40)
0.75 0.93
(0.61e1.43)
0.75 0.93
(0.62e1.40)
0.73
15,000 46 (11.27) 183 (11.08) 0.98
(0.66e1.46)
0.91 1.02
(0.57e1.81)
0.96 1.01
(0.67e1.51)
0.98
15,001e
29,999
18 (4.41) 87 (5.27) 0.83
(0.47e1.45)
0.52 0.84
(0.42e1.67)
0.61 0.83
(0.47e1.46)
0.52
30,000 14 (3.43) 73 (4.42) 0.79
(0.43e1.46)
0.45 0.80
(0.37e1.72)
0.57 0.79
(0.43e1.48)
0.46
>30,000 35 (8.58) 151 (9.15) 0.83
(0.54e1.28)
0.40 0.84
(0.45e1.55)
0.58 0.83
(0.53e1.29)
0.41
OR: odds ratio; CI: confidence interval; ICS: inhaled corticosteroid; LABA: long-acting inhaledb2-agonists; LAMA: long-acting inhaled
muscarinic antagonists; SD: standard deviation; Q1: first quartile; Q3: third quartile.
a Defined if inhaler prescriptions shorter than 30 days during 1 year before the index date was identified.
b Defined if inhaler prescriptions 30 days or longer during 1 year before the index date was identified.
c Adjusted for LABA use, LAMA use, SABA use, SAMA use, OCS use.
d Adjusted for LAMA use, SABA use, SAMA use, OCS use.
e Linear logit model: used each group median.
Inhaled corticosteroids and lung/laryngeal cancers 12290.53e1.13) were not associated with the risk of laryngeal
cancer. Even with a cumulative ICS dose greater than
30,000 mg, no reduction in the risk of laryngeal cancer was
observed (aOR, 0.84; 95% CI, 0.45e1.55; Table 4). Sensi-
tivity analyses using 3- and 6-month lag-time analyses
showed similar results (Table 5).Discussion
The global burden of cancer continues to increase largely
because of the aging and growth of the world population
and the increasing adoption of cancer-causing behaviors,
particularly smoking in economically developing countries.
The lung is the leading cancer site in males, and lung canceraccounts for 17% of all new cancer cases and 23% of total
cancer deaths.33 It is also common in females as the fourth
most common cancer. In addition, nasopharyngeal cancer is
the twenty-fourth most common cancer in the world.33
Patients with COPD15,16 and asthma,17 are a high risk
group for development of lung cancer. Our results showed
that ICS use reduces the risk for lung cancer but not for
laryngeal cancer.
The inverse relationship between ICS use and a diagnosis
of lung cancer can be understood through the anti-
inflammatory effects of steroids. The concept that inflam-
mation is a critical component of tumor progression has
been widely accepted. Many cancers arise from sites of
infection, chronic irritation, and inflammation. Inflamma-
tory conditions are present before a malignant change
Table 5 Sensitivity analysis for risk of laryngeal cancer according to use of inhalers.
Laryngeal cancer (N Z 408) Control (N Z 1651) Crude OR (95% CI) p-value Adjusted OR (95% CI) p-valuec Adjusted OR (95% CI) p-valued
Use of inhalers till 3 months prior to index date
ICS
Non-ICS usersa 342 (83.82) 1377 (83.40) 1(ref) 1(ref) 1(ref)
ICS usersb 66 (16.18) 274 (16.60) 0.76 (0.53e1.11) 0.16 0.90 (0.39e2.09) 0.81 0.77 (0.53e1.13) 0.19
LABA
Non-LABA usersa 348 (85.29) 1400 (84.80) 1(ref) 1(ref)
LABA userb 60 (14.71) 251 (15.20) 0.75 (0.52e1.1) 0.14 0.84 (0.36e1.96) 0.69
LAMA
Non-LAMA usersa 383 (93.87) 1546 (93.64) 1(ref) 1(ref) 1(ref)
LAMA userb 25 (6.13) 105 (6.36) 0.67 (0.41e1.11) 0.12 0.68 (0.41e1.13) 0.14 0.68 (0.41e1.13) 0.13
Cumulative dose of ICS (mg)
Mean (SD) 36,424.07 (58,900.25) 36,149.77 (51,164.46)
Median (Q1, Q3) 15,000 (15,000, 37,125) 15,125 (15,000, 37,500)
P value for trende 0.04 0.08 0.05
0 dose 273 (66.91) 1133 (68.63) 1(ref) 1(ref) 1(ref)
<5000 13 (3.19) 56 (3.39) 0.57 (0.29e1.15) 0.12 0.56 (0.28e1.13) 0.10 0.56 (0.28e1.13) 0.10
5000e14,999 18 (4.41) 58 (3.51) 0.84 (0.46e1.56) 0.59 0.79 (0.41e1.50) 0.47 0.78 (0.41e1.47) 0.44
15000 50 (12.25) 142 (8.60) 1.04 (0.67e1.62) 0.86 1.01 (0.62e1.67) 0.96 1.00 (0.63e1.58) 0.99
15,001e29,999 4 (0.98) 44 (2.67) 0.28 (0.1e0.81) 0.02 0.28 (0.09e0.85) 0.03 0.28 (0.09e0.8) 0.02
30000 14 (3.43) 74 (4.48) 0.50 (0.26e0.98) 0.04 0.49 (0.24e1.02) 0.06 0.48 (0.24e0.94) 0.03
>30,000 36 (8.82) 144 (8.72) 0.63 (0.38e1.04) 0.07 0.62 (0.34e1.16) 0.14 0.61 (0.36e1.01) 0.06
Use of inhalers till 6 months prior to index date
ICS
Non-ICS usersa 365 (89.46) 1477 (89.46) 1(ref) 1(ref) 1(ref)
ICS usersb 43 (10.54) 174 (10.54) 0.75 (0.48e1.18) 0.21 0.91 (0.35e2.40) 0.85 0.72 (0.46e1.14) 0.17
LABA
Non-LABA usersa 369 (90.44) 1490 (90.25) 1(ref) 1(ref)
LABA userb 39 (9.56) 161 (9.75) 0.73 (0.47e1.15) 0.18 0.77 (0.29e2.03) 0.60
LAMA
Non-LAMA usersa 392 (96.08) 1589 (96.24) 1(ref) 1(ref) 1(ref)
LAMA userb 16 (3.92) 62 (3.76) 0.64 (0.34e1.2) 0.16 0.62 (0.33e1.18) 0.15 0.62 (0.33e1.18) 0.15
Cumulative dose of ICS(mg)
Mean (SD) 36,056.82 (53,448.90) 35,182.01 (45,840.52)
Median (Q1, Q3) 15,000 (15,000, 45,000) 15,500 (15,000, 40,000)
(continued on next page)
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Inhaled corticosteroids and lung/laryngeal cancers 1231occurs in some types of cancer. However, a malignant
change antecedes an inflammation that promotes the
development of tumorism other cancers. Irrespective of
their origin, inflammatory cells and cytokines found in
tumors contribute to tumor growth and progression and the
suppression of an effective host antitumor response.11,12,34
The links between chronic inflammation and lung cancer is
well known.35 In addition, allergic respiratory inflammation
promotes the recruitment of circulating tumor cells in
mice, thus promoting lung metastasis.36 Corticosteroids,
the most potent anti-inflammatory drugs, could suppress
the chronic inflammatory process and, subsequently, the
tumor-promoting effects of inflammation. In fact, non-
steroidal anti-inflammatory drugs, another potent class of
anti-inflammatory drugs, are proposed to have a protective
effect on lung cancer in a meta-analysis.37
A previous study exploring the association between ICS
use and development of lung cancer using a cohort of
10,474 US veterans with COPD suggested a reduction in lung
cancer with ICS use.14 That result was confirmed in our
study, which analyzed a cohort of 792,687 new users of
inhaled respiratory medication.
Several reasons exist to expect the same protective
effect of ICS on laryngeal cancer. Lung cancer and laryngeal
cancer have common predisposing factors, smoking, the
most prominent environmentally predisposing factor.38
Smoking is a potent inducer of inflammation and plays
a key role in carcinogenesis throughout the respiratory
tract.39,40 The links between chronic inflammation and both
lung cancer35 and laryngeal cancer41 are well established.
Additionally, deposition of some portion of the inhaled
medication in upper airways is inevitable.42 However, we
failed to identify an association between ICS use and
development of laryngeal cancer (Table 5).
The differential effect of ICS on the development of lung
cancer or laryngeal cancer might be explained by the
amount of inhaled ICS deposited. Although more than half
of the emitted dose deposits are in the upper airway, most
of the drugs are removed from the oral cavity, oropharynx,
or larynx by rinsing and swallowing.43 Given that the
preventive effect of ICS on lung cancer was dose dependent
in our study, the amount of ICS deposited on the larynx
might be lower than the threshold for a preventive effect
on carcinogenesis in laryngeal cancer.
ICS use is associated with various systemic adverse
effects such as diabetes,44 adrenal insufficiency,45 osteo-
porosis/fracture,46 and cataracts.47 Considering these
unwanted adverse effects, reduction of ICS side effects by
combining ICS with other inhaled respiratory medications in
asthma48 and use of ICS in patients with more advanced
COPD2 are recommended. However, our data suggests the
presence of unintended beneficial effects of ICS. How to
adopt this beneficial effect should be investigated, if it is
confirmed in future studies.
Interestingly, LAMA use showed a positive association
with lung cancer in our study. However, in the sensitivity
analysis, ignoring the use of ICS within the lag time (3 or 6
months) prior to the index date, the statistical significance
of the association disappeared (Table 3). The association
between LAMA use and lung cancer in the original analysis
might be due to ‘protopathic bias’32 rather than to a true
harmful effect. In addition, the risk of lung cancer did not
1232 C.-H. Lee et al.decrease in patients with the highest cumulative dose of
ICS. However, sensitivity analysis resulted in decreased risk
of lung cancer among highest cumulative dose ICS users.
These results also raise the possibility of protopathic bias.
To appreciate our results, the strengths and limitations
of this study must be acknowledged. One of the main
strengths of this study was that it was based on a nation-
wide database, which minimized the likelihood of selection
bias. Additionally, we avoided protopathic bias, which
occurs when early symptoms of undetected cancer affect
the use of ICS, through a sensitivity analysis using 3- and 6-
month lag-time analysis. The most important limitation of
this study was that smoking status of inhaled respiratory
medications users was not available. Selecting controls
from users of other inhaled respiratory medications and
matching important variables such as age, sex, asthma, or
COPD, Charlson Comorbidity Index scores, and health care
utilization could minimize the confounding effects of
smoking on the results of this study.
In conclusion, exposure to ICS was associated with
a reduced risk of lung cancer but not laryngeal cancer.
Confirmation of these findings in different cohorts and
discussion on proper application of the findings to clinical
practice are needed.
Acknowledgment
None of the authors have potential conflict of interest.Financial disclosure
This study was funded by the National Evidence-based
Healthcare Collaborating Agency (NECA), project no.
NC2011-004.Conflict of interest
None declared.
References
1. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for
asthma management and prevention: GINA executive
summary. Eur Respir J 2008;31:143e78.
2. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS.
Global strategy for the diagnosis, management, and preven-
tion of chronic obstructive pulmonary disease. NHLBI/WHO
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Workshop summary. Am J Respir Crit Care Med 2001;163:
1256e76.
3. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH,
O’Byrne PM, Hargreave FE. Effect of long-term treatment with
an inhaled corticosteroid (budesonide) on airway hyper-
responsiveness and clinical asthma in nonsteroid-dependent
asthmatics. Am Rev Respir Dis 1990;142:832e6.
4. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of
inhaled formoterol and budesonide on exacerbations of
asthma. Formoterol and Corticosteroids Establishing
Therapy (FACET) International Study Group. N Engl J Med
1997;337:1405e11.5. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose
inhaled corticosteroids and the prevention of death from
asthma. N Engl J Med 2000;343:332e6.
6. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary
management of chronic obstructive pulmonary disease: scien-
tific review. J Am Med Assoc 2003;290:2301e12.
7. Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of
stable chronic obstructive pulmonary disease: a systematic review
for a clinical practice guideline.Ann InternMed 2007;147:639e53.
8. Jeffery PK, Godfrey RW, Adelroth E, Nelson F, Rogers A,
Johansson SA. Effects of treatment on airway inflammation and
thickening of basement membrane reticular collagen in
asthma. A quantitative light and electron microscopic study.
Am Rev Respir Dis 1992;145:890e9.
9. Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE.
Effects of high-density lipoprotein on acetylcholine-induced
coronary vasoreactivity. Am J Cardiol 1991;68:1425e30.
10. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC.
The effects of inhaled fluticasone on airway inflammation in
chronic obstructive pulmonary disease: a double-blind,
placebo-controlled biopsy study. Am J Respir Crit Care Med
2002;165:1592e6.
11. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;
420:860e7.
12. Balkwill F, Mantovani A. Inflammation and cancer: back to
Virchow? Lancet 2001;357:539e45.
13. Fu H, Zhang J, Pan J, et al. Chemoprevention of lung carci-
nogenesis by the combination of aerosolized budesonide and
oral pioglitazone in A/J mice. Mol Carcinog 2011;50:913e21.
14. Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH.
Inhaled corticosteroids and risk of lung cancer among patients
with chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 2007;175:712e9.
15. Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD. Relationship
between reduced forced expiratory volume in one second and
the risk of lung cancer: a systematic review and meta-analysis.
Thorax 2005;60:570e5.
16. van de Schans SA, Janssen-Heijnen ML, Biesma B, et al. COPD
in cancer patients: higher prevalence in the elderly, a different
treatment strategy in case of primary tumours above the dia-
phragm, and a worse overall survival in the elderly patient. Eur
J Cancer 2007;43:2194e202.
17. Santillan AA, Camargo Jr CA, Colditz GA. A meta-analysis of
asthma and risk of lung cancer (United States). Cancer Causes
Control 2003;14:327e34.
18. Kim DS. Introduction: health of the health care system in
Korea. Soc Work Public Health 2010;25:127e41.
19. Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism
in Korea: from the Health Insurance Review and Assessment
Service database. J Thromb Haemost 2011;9:85e91.
20. Kim NH, Kim HJ, Cheong HK, et al. Prevalence of multiple
sclerosis in Korea. Neurology 2010;75:1432e8.
21. Kang HY, Yang KH, Kim YN, et al. Incidence and mortality of hip
fracture among the elderly population in South Korea: a pop-
ulation-based study using the national health insurance
claims data. BMC Public Health 2010;10:230.
22. Lee JH, Park YS, Choi JS. The epidemiology of appendicitis and
appendectomy in South Korea: national registry data. J Epi-
demiol 2010;20:97e105.
23. Kim HA, Kim S, Seo YI, et al. The epidemiology of total knee
replacement in South Korea: national registry data. Rheuma-
tology (Oxford) 2008;47:88e91.
24. National Asthma Education and Prevention Program, National
Heart, Lung, and Blood Institute. Expert panel report 3:
guidelines for the diagnosis and management of asthma.
National Institutes of Health. Publication No. 07e4051. Avail-
able from: http://www.nhlbi.nih.gov/guidelines/asthma/asthg
dln.htm; 2007 [accessed Aug 2011].
Inhaled corticosteroids and lung/laryngeal cancers 123325. Boulet LP, Becker A, Berube D, Beveridge R, Ernst P. Canadian
asthma consensus report, 1999. Canadian Asthma Consensus
Group. CMAJ 1999;161:S1e61.
26. GINA. Global strategy for asthma management and prevention
2010 (update) 2010.
27. Wertheimer AI. The defined daily dose system (DDD) for drug
utilization review. Hosp Pharm 1986;21:233e4. 9-41, 58.
28. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticoste-
roid use in chronic obstructive pulmonary disease and the risk
of hospitalization for pneumonia. Am J Respir Crit Care Med
2007;176:162e6.
29. D’Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome
assessment: the Charlson comorbidity index. Methods Inf Med
1993;32:382e7.
30. Needham DM, Scales DC, Laupacis A, Pronovost PJ. A system-
atic review of the Charlson comorbidity index using Canadian
administrative databases: a perspective on risk adjustment in
critical care research. J Crit Care 2005;20:12e9.
31. Arlt W. Disorders of the adrenal cortex. In: Longo DL, Fauci A,
Kasper D, Hauser S, Jameson JL, Loscalzo J, editors. Harrison’s
principles of internal medicine. 18th ed. McGraw-Hill Profes-
sional; 2011.
32. Horwitz RI, Feinstein AR. The problem of “protopathic bias” in
case-control studies. Am J Med 1980;68:255e8.
33. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.
Global cancer statistics. CA Cancer J Clin 2011;61:69e90.
34. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related
inflammation. Nature 2008;454:436e44.
35. GompertsBN, SpiraA,MassionPP,et al. Evolvingconcepts in lung
carcinogenesis. Semin Respir Crit Care Med 2011;32:32e43.
36. Taranova AG, Maldonado 3rd D, Vachon CM, et al. Allergic
pulmonary inflammation promotes the recruitment of circu-
lating tumor cells to the lung. Cancer Res 2008;68:8582e9.37. Khuder SA, Herial NA, Mutgi AB, Federman DJ. Nonsteroidal
antiinflammatory drug use and lung cancer: a metaanalysis.
Chest 2005;127:748e54.
38. Carbone D. Smoking and cancer. Am J Med 1992;93:13Se7S.
39. Brody JS, Spira A. State of the art. Chronic obstructive
pulmonary disease, inflammation, and lung cancer. Proc Am
Thorac Soc 2006;3:535e7.
40. Smith CJ, Perfetti TA, King JA. Perspectives on pulmonary
inflammation and lung cancer risk in cigarette smokers. Inhal
Toxicol 2006;18:667e77.
41. Wang F, Arun P, Friedman J, Chen Z, Van Waes C. Current and
potential inflammation targeted therapies in head and neck
cancer. Curr Opin Pharmacol 2009;9:389e95.
42. Leach CL. Improved delivery of inhaled steroids to the large
and small airways. Respir Med 1998;92(Suppl. A):3e8.
43. Laube BL, Janssens HM, de Jongh FH, et al. What the pulmo-
nary specialist should know about the new inhalation thera-
pies. Eur Respir J 2011;37:1308e31.
44. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks
of diabetes onset and progression. Am J Med 2010;123:1001e6.
45. Masoli M, Weatherall M, Holt S, Shirtcliffe P, Beasley R. Inhaled
fluticasone propionate and adrenal effects in adult asthma:
systematic review and meta-analysis. Eur Respir J 2006;28:
960e7.
46. Richy F, Bousquet J, Ehrlich GE, et al. Inhaled corticosteroids
effects on bone in asthmatic and COPD patients: a quantitative
systematic review. Osteoporos Int 2003;14:179e90.
47. Weatherall M, Clay J, James K, Perrin K, Shirtcliffe P,
Beasley R. Doseeresponse relationship of inhaled corticoste-
roids and cataracts: a systematic review and meta-analysis.
Respirology 2009;14:983e90.
48. Sears MR. The addition of long-acting beta-agonists to inhaled
corticosteroids in asthma. Curr Opin Pulm Med 2011;17:23e8.
